England to Screen Newborns for Spinal Muscular Atrophy in 2027

England will introduce nationwide newborn screening for spinal muscular atrophy from October 2027 to support earlier diagnosis and treatment.

England will roll out nationwide screening for Spinal Muscular Atrophy (SMA) beginning in October 2027, ensuring that every newborn in the country is tested through the routine NHS newborn blood spot test. The move aims to identify affected infants earlier so they can receive treatment before symptoms develop (1^✔ ✔Trusted Source
Every baby in England to get life-saving genetic test from birth

Go to source

).
The announcement marks a significant expansion of England’s newborn screening program following successful evaluations of the testing process. Spinal Muscular Atrophy affects approximately 1 in 10,000 babies and is a rare genetic condition that can cause progressive muscle weakness and severe disability if not diagnosed promptly.

What Is Spinal Muscular Atrophy and How Does It Affect Newborns?

Spinal Muscular Atrophy is a rare inherited condition that affects the nerves controlling muscle movement. It is caused by changes in the SMN1 gene and can lead to muscle weakness, breathing difficulties, and mobility challenges. Early diagnosis is especially important because treatment before symptoms appear has been shown to improve outcomes.

How Will England’s Newborn Screening Program Detect Spinal Muscular Atrophy?

All babies in England will be screened for Spinal Muscular Atrophy through the NHS newborn blood spot test, commonly known as the heel prick test, which is carried out around five days after birth. The test currently screens for several rare but serious health conditions and will be expanded to include SMA.

Initially, seven laboratories in England will begin screening as part of an in-service evaluation before testing is expanded to all 13 NHS laboratories nationwide by October 2027.

Why Early Diagnosis of Spinal Muscular Atrophy Is Important for Babies

Early identification allows babies with Spinal Muscular Atrophy to receive treatment before symptoms emerge, helping reduce irreversible disease progression. Healthcare professionals and patient advocacy groups have long supported newborn screening because treatment is most effective when administered as early as possible.

Campaigners and families affected by the condition welcomed the announcement, describing it as a landmark development for newborn health and rare disease care across England.

England’s Nationwide Spinal Muscular Atrophy Screening Marks a Major Milestone

The nationwide rollout is expected to provide equitable access to screening across England and strengthen the country’s approach to early detection of rare genetic conditions. Scotland has already introduced a pilot screening program for Spinal Muscular Atrophy, while Wales and Northern Ireland have yet to announce similar plans.

Reference:

1. Every baby in England to get life-saving genetic test from birth – (https://www.gov.uk/government/news/every-baby-in-england-to-get-life-saving-genetic-test-from-birth)

Source-Medindia